Hiroki Higashi

Gd-EOB-DTPA-enhanced MR imaging: Evaluation of hepatic enhancement effects in normal and cirrhotic livers

OBJECTIVE The purpose of this study was to assess differences in enhancement effects of liver parenchyma between normal and cirrhotic livers on contrast-enhanced MR imaging (CE-MRI) obtained with Gd-EOB-DTPA. METHODS A total of 99 patients with cirrhotic liver (n=58; Child-Pugh class A, n=30; B, n=22; C, n=6) and normal liver (n=41) underwent Gd-EOB-DTPA-enhanced MR imaging. CE images were obtained before contrast injection, in the arterial phase (AP) at 25s or modified scan delay, in the portal phase (PP) at 70s, in the equilibrium phase (EP) at 3 min, and in the hepatobiliary phase (HP) at 3 times (10, 15 and 20 min). Signal intensity of the liver in all phases was defined using region-of-interest measurements for relative enhancement (RE) calculation. RESULTS In normal-liver and Child-Pugh class A and B patients, mean RE of liver parenchyma increased significantly (P<0.03-0.001) with time until 20-min HP. Conversely, mean RE for Child-Pugh class C patients did not show any increasing tendency after PP. Mean RE of liver parenchyma at EP and HP (10-, 15- and 20-min) was highest in normal liver, followed by Child-Pugh class A, B and C cirrhosis (P<0.02-0.001). CONCLUSION Hepatic parenchymal enhancement on CE-MR images obtained using Gd-EOB-DTPA is affected by the severity of cirrhosis.

Dynamic contrast-enhanced magnetic resonance imaging of abdominal solid organ and major vessel: comparison of enhancement effect between Gd-EOB-DTPA and Gd-DTPA.

To evaluate the differences in enhancement of the abdominal solid organ and the major vessel on dynamic contrast‐enhanced magnetic resonance imaging (DCE‐MRI) obtained with gadolinium ethoxybenzyldiethylenetriamine pentaacetic acid (Gd‐EOB‐DTPA: EOB) and gadolinium diethylenetriamine pentaacetic acid (Gd‐DTPA) in the same patients.

Locally Recurrent Prostate Cancer After High-Dose-Rate Brachytherapy: The Value of Diffusion-Weighted Imaging, Dynamic Contrast-Enhanced MRI, and T2-Weighted Imaging in Localizing Tumors

OBJECTIVE The purpose of this article is to retrospectively evaluate the utility of prostate MRI for detecting locally recurrent prostate cancer after high-dose-rate (HDR) brachytherapy. MATERIALS AND METHODS Sixteen men with biochemical failure after HDR brachytherapy for prostate cancer underwent prostate MRI, including T2-weighted imaging, dynamic contrast-enhanced MRI (DCE-MRI), and diffusion-weighted imaging (DWI), using a 1.5-T MRI unit before 12-core-specimen biopsy. Two radiologists in consensus assessed the presence of tumor on each sequence within eight regions of the prostate (six from the peripheral zone [PZ] and two from the transition zone [TZ]) on the basis of biopsy. RESULTS Biopsy revealed locally recurrent prostate cancer in 22 (17 in PZ and five in TZ) of 128 regions (17.2%). The sensitivity, specificity, and accuracy of each MRI method in the detection of recurrent tumor were 27%, 99%, and 87%, respectively, for T2-weighted imaging; 50%, 98%, and 90%, respectively, for DCE-MRI; and 68%, 95%, and 91%, respectively, for DWI. The sensitivity of DWI in detecting recurrent tumor was significantly higher than that of T2-weighted imaging (p = 0.004). Multiparametric MRI achieved the highest sensitivity (77%) but with slightly decreased specificity (92%). CONCLUSION These results indicate that a multiparametric MRI protocol that includes DWI provides a sensitive method to detect local recurrence after HDR brachytherapy.

High b Value (2,000 s/mm2) Diffusion-Weighted Magnetic Resonance Imaging in Prostate Cancer at 3 Tesla: Comparison with 1,000 s/mm2 for Tumor Conspicuity and Discrimination of Aggressiveness

Objective The objective of our study was to investigate tumor conspicuity and the discrimination potential for tumor aggressiveness on diffusion-weighted magnetic resonance imaging (DW-MRI) with high b value at 3-T. Materials and Methods The institutional review board approved this study and waived the requirement for informed consent. A total of 50 patients with prostate cancer (69 cancer foci; 48 in the PZ, 20 in the TZ, and one in whole prostate) who underwent multiparametric prostate MRI including DW-MRI (b values: 0, 1000 s/mm2 and 0, 2000 s/mm2) on a 3-T system were included. Lesion conspicuity score (LCS) using visual assessment (1 = invisible for surrounding normal site; 2 = slightly high intensity; 3 = moderately high; and 4 = very high) and tumor-normal signal intensity ratio (TNR) were assessed, and apparent diffusion coefficient (ADC, ×10−3 mm2/s) of the tumor regions and normal regions were measured. Results Mean LCS and TNR at 0, 2000 s/mm2 was significantly higher than those at 0, 1000 s/mm2 (p<0.001 for both). In addition, ADC at both 0, 1000 and 0, 2000 s/mm2 was found to distinguish intermediate or high risk cancer with Gleason score ≥7 from low risk cancer with Gleason score ≤6 (p<0.001 for both). Furthermore, ADC of tumor regions correlated with Gleason score at both 0, 1000 s/mm2 (ρ = −0.602; p<0.001) and 0, 2000 s/mm2 (ρ = −0.645; p<0.001). Conclusions For tumor conspicuity and characterization of prostate cancer on DW-MRI of 3-T MRI, b = 0, 2000 s/mm2 is more useful than b = 0, 1000 s/mm2.

Gd-EOB-DTPA enhanced MR imaging: evaluation of biliary and renal excretion in normal and cirrhotic livers.

OBJECTIVE The purpose of this study was to assess the difference in the activity of biliary and renal excretion between normal and cirrhotic livers on contrast-enhanced MR imaging obtained with gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA). METHODS A total of 78 patients with cirrhotic liver (n=44) and with normal liver (n=34) underwent multi-phase Gd-EOB-DTPA enhanced MR imaging (arterial, portal, equilibrium, and three hepatobiliary phases (10, 15 and 20 min HP), respectively), and these contrast-enhanced images were qualitatively and quantitatively evaluated for the differences of the biliary and renal excretion between normal and cirrhotic livers. RESULTS The timing of biliary excretion of contrast agents in the cirrhotic liver was significantly slower than that in the normal liver (P<0.001). The degree of contrast enhancement in the common bile duct in the normal liver was significantly better than that in the cirrhotic liver (P=0.003). Contrast agents were demonstrated in the duodenum at 20 min HP in 8/44 (18%) cirrhotic liver while they were seen in 15/34 (44%) normal liver (P=0.013). The enhancement effects of renal medulla and portal vein at 20 min HP in the cirrhotic liver were significantly higher than those of normal liver (P=0.043 and P<0.001, respectively). CONCLUSION Biliary excretion of Gd-EOB-DPTA was impaired in cirrhotic livers in comparison with normal livers while renal excretion of Gd-EOB-DPTA was increased.

Hepatic Hemangiomas: Evaluation of Enhancement Patterns at Dynamic MRI With Gadoxetate Disodium

OBJECTIVE The aim of this retrospective study was to assess the enhancement patterns of hepatic hemangiomas on gadoxetate disodium. MATERIALS AND METHODS A total of 22 patients with 32 hepatic hemangiomas (23 typical type and nine high-flow type) in normal liver underwent gadoxetate disodium-enhanced MRI. Contrast-enhanced images were obtained before and after contrast injection, including arterial phase, portal phase, equilibrium phase, and three hepatobiliary phases (10, 15 and 20 minutes). Signal-to-phantom ratios of hemangiomas and the portal vein as well as lesion-to-liver contrast-to-phantom ratios were assessed. RESULTS Mean signal-to-phantom ratios of all 32 hemangiomas showed the highest value on the arterial phase and subsequently decreased over time (p = 0.029 to p < 0.001). Mean lesion-to-liver contrast-to-phantom ratios of all 32 hemangiomas showed a positive value during the arterial phase and increasingly negative values at later time points (p = 0.001 to p < 0.001). The enhancement pattern of hemangiomas was equal to that of the portal vein at all time points. There was no significant difference in signal-to-phantom ratio between typical hemangiomas and high-flow hemangiomas at any time point. CONCLUSION Most hepatic hemangiomas showed hypointensity relative to surrounding liver parenchyma during the equilibrium phase and the hepatobiliary phase. In addition, hepatic hemangiomas showed a signal intensity matching the portal vein at all phases, a finding we believe may be characteristic for hepatic hemangiomas on gadoxetate disodium-enhanced MR images.

Potential clinical factors affecting hepatobiliary enhancement at Gd-EOB-DTPA-enhanced MR imaging.

OBJECTIVE The objective was to clarify the clinical factors that might affect the degree of hepatic parenchymal enhancement at gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance (MR) imaging. MATERIALS AND METHODS A total of 84 patients with (n=63) and without chronic liver disease (n=21) underwent Gd-EOB-DTPA-enhanced MR imaging. Contrast-enhanced MR images of hepatobiliary phase (HP) were obtained at 20 min after Gd-EOB-DTPA administration. The relative enhancement (RE) of liver parenchyma at 20 min HP was calculated from region of interest measurements at each patient. Then, these results were correlated with various clinical parameters using Pearson correlation coefficient or Spearman rank correlation coefficient. Furthermore, the predictor of the degree of hepatic parenchymal enhancement was determined using multiple regression analysis. RESULTS The presence or absence of chronic liver disease (P=.002), ascites (P=.005) and splenomegaly (P=.027), and the values of prothrombin activity (P=.008), total bilirubin (T-Bil) (P=.001), albumin (P=.001), aspartate aminotransferase (AST) (P=.002) and cholinesterase (P=.007) were significantly correlated with the RE of liver parenchyma at 20 min HP. Among these parameters, increases of T-Bil (P=.011 to .028) and AST (P=.018 to .049) were predictors of decreased hepatic parenchymal enhancement. CONCLUSIONS Hepatic parenchymal enhancement of Gd-EOB-DTPA was affected by various clinical parameters. Impaired hepatobiliary enhancement may be predicted by routine biochemical tests, such as T-Bil and AST.

High-risk nodules detected in the hepatobiliary phase of Gd-EOB-DTPA-enhanced MR imaging in cirrhosis or chronic hepatitis: incidence and predictive factors for hypervascular transformation, preliminary results.

To evaluate the incidence and predictive factors of hypervascular transformation during follow‐up of “high‐risk nodules” detected in the hepatobiliary phase of initial Gd‐EOB‐DTPA‐enhanced MRI in chronic liver disease patients.

Hepatic parenchymal enhancement at Gd-EOB-DTPA-enhanced MR imaging: correlation with morphological grading of severity in cirrhosis and chronic hepatitis

The aim was to clarify whether enhancement effects of the liver parenchyma in the hepatobiliary phase (HP) of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced MR imaging were correlated with the morphological grading of the severity in cirrhosis. A total of 62 patients with chronic hepatitis or cirrhosis underwent Gd-EOB-DTPA-enhanced MR imaging. Relative enhancement (RE) of liver parenchyma was calculated from signal intensity (SI) measurements obtained at precontrast images (SIpre) and 20-min postcontrast HP images (SIpost) as: (SIpost-SIpre)/SIpre. Morphological MR grades of severity in cirrhosis were divided into four groups. Then, RE of liver parenchyma and morphologic MR grading were correlated. Regarding the morphologic severity of cirrhosis, the numbers of patients with MR grade 1, 2, 3 and 4 were 14 (23%), 7 (11%), 28 (45%) and 13 (21%), respectively. The mean REs of liver parenchyma in each group of MR morphologic grade 1, 2, 3 and 4 were 0.71±0.21, 0.62±0.16, 0.70±0.22 and 0.77±0.18, respectively. There was no significant correlation between the MR grading of morphologic severity and the RE of liver parenchyma at 20-min HP. Hepatic parenchymal enhancement in the HP of Gd-EOB-DTPA-enhanced MR imaging did not necessarily decrease according to the severity of morphologic changes in cirrhosis. This fact may suggest that the hepatic uptake of Gd-EOB-DTPA depends on the preserved hepatocytes function rather than the severity of morphologic changes in cirrhosis.

Comparison of three different injection methods for arterial phase of Gd-EOB-DTPA enhanced MR imaging of the liver

OBJECTIVE To compare three different injection methods for optimizing hepatic arterial phase of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA) enhanced MR imaging. METHODS Arterial phase images were obtained after the injection of contrast agent at a rate of 3 mL/s with diluted Gd-EOB-DTPA (dilution method) in 27 patients, 3 mL/s with undiluted Gd-EOB-DTPA (3 mL method) in 26 patients and 1 mL/s with undiluted Gd-EOB-DTPA (1 mL method) in 28 patients. In the quantitative evaluation, signal-to-phantom ratios (SPR) of the liver parenchyma, pancreas, renal cortex, portal vein and aorta were evaluated. In the qualitative evaluation, the seven items for image quality of hepatic arterial phase were assessed, and the total score of all items in each subject was calculated. RESULTS The score of enhancement of abdominal aorta and total score of seven items in 1 mL method were significantly higher than those in 3 mL method. The SPR of the liver parenchyma in 3 mL method was significantly higher than that in 1 mL method, suggesting substantial hepatic inflow from portal venous return. CONCLUSION For the optimal arterial phase imaging, injection rate of 1 mL/s with undiluted Gd-EOB-DTPA is convenient and preferable, compared with other two methods, based on our qualitative analysis.